LumiThera has filed a notice of an exempt offering of securities to raise $5 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, LumiThera is raising up to $5,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Clark Tedford played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About LumiThera
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Companys expertise is in the application of photobiomodulation (PBM), using non-invasive light emitting diodes (LED) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments.
To learn more about LumiThera, visit http://www.lumithera.com/
Contact:
Clark Tedford, President and Chief Executive Officer
360-536-5119
https://www.linkedin.com/in/clark-tedford-8284a45/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.